Profitability Trajectories: Eli Lilly, Pfizer, and Merck's 15-Year Performance

Tracking DuPont trends is crucial for understanding how companies create shareholder value over time. By analyzing the components of Return on Equity (ROE)—net margin, asset turnover, and equity multiplier—we can gain insights into each company's operational efficiency and financial strategy across different economic regimes.

Over the past 15 years, Eli Lilly and Merck have demonstrated significant improvements in ROE, while Pfizer has remained stable. During the pre-COVID period, Eli Lilly's ROE surged from 40.8% in 2010 to 74.6% in 2024, largely driven by increased leverage as reflected in its equity multiplier, which rose from 2.5 to 5.5. In contrast, Pfizer's ROE slightly declined from 9.4% to 9.1% over the same period, indicating a lack of growth momentum in profitability despite stable net margins. Merck experienced a remarkable recovery from a low ROE of 1.6% in 2010 to 37.0% in 2024, mainly due to a substantial increase in net margins from 1.9% to 26.7%, indicating successful pricing strategies and operational efficiencies, particularly during the COVID recovery phase when many companies faced challenges. The COVID-19 pandemic significantly impacted the pharmaceutical sector, with Eli Lilly and Merck adapting more effectively than Pfizer. The ensuing recovery in 2021 saw both companies capitalize on rising demand for their products, resulting in improved margins and efficiency metrics. However, in 2022, as interest rates began to rise, the companies faced margin pressures due to increased operational costs, but Eli Lilly maintained its upward trajectory in ROE due to its strong leverage position. Merck, on the other hand, faced challenges in maintaining asset turnover but managed to sustain growth through improved profit margins. Overall, the trends suggest that while Eli Lilly and Merck have navigated through economic fluctuations with strategic positioning and operational excellence, Pfizer's relative stagnation in ROE highlights a need for renewed strategic focus.

Eli Lilly's ROE has shown a consistent upward trend, particularly benefiting from enhanced leverage during the low-rate environment of 2020-2021. Merck's trajectory illustrates a remarkable recovery, with substantial margin expansion during the post-COVID recovery phase. In contrast, Pfizer's ROE has remained relatively stable, reflecting its struggle to enhance profitability in a rapidly evolving market landscape.

Understanding margin trends through economic cycles provides critical insight into a company's operational resilience and competitive positioning. It highlights how effectively a company can manage costs and pricing power over time, beyond mere point-in-time financial metrics.

From 2010 to 2024, the pharmaceutical sector faced significant disruptions and transformations, particularly highlighted by the COVID-19 pandemic in 2020. During this period, Eli Lilly (LLY) maintained a stable gross margin of 81.3%, showing resilience amid supply chain challenges and shifting consumer demand. In contrast, Pfizer (PFE) experienced a decline in gross margin from 69.1% to 65.8%, reflecting pressures on pricing power and increased competition. Merck (MRK), however, demonstrated a remarkable improvement in gross margin, soaring from 60.0% to 76.3%, indicating strong pricing strategies and cost efficiencies during this turbulent period. The reopening boom in 2021 brought renewed demand, with LLY capitalizing on its operational efficiencies to improve its operating margin from 29.3% in 2010 to 38.9% in 2024. Meanwhile, MRK's operating margin surged from 7.3% to 31.5%, showcasing effective scaling and a robust recovery strategy. Conversely, PFE's operating margin remained relatively stable, decreasing slightly from 26.4% to 25.9%, suggesting challenges in managing operational costs amid inflationary pressures. As inflation escalated in 2021 and 2022, the ability to maintain margins became paramount. LLY and MRK effectively managed their cost structures to sustain stable net margins, while PFE's net margin remained relatively unchanged at 12.6%. This indicates varying levels of success in passing on costs to consumers or optimizing operational efficiency. Overall, the differing trajectories highlight how each company navigated inflationary pressures and interest rate hikes that followed, particularly as the Federal Reserve initiated a rate hike cycle in 2022, which posed additional challenges to profitability.

The gross margin analysis reveals that while LLY's margin remained stable, MRK's significant improvement indicates strong pricing power and effective cost management, particularly during inflationary periods. PFE's decline in gross margin, from 69.1% to 65.8%, suggests increased challenges in maintaining pricing amid rising costs.

Operating margins tell a compelling story of cost discipline during the COVID disruption, with LLY and MRK exhibiting gains through strategic management. However, the pressures from rising labor costs and interest rates beginning in 2022 led to a stabilization in PFE's operating margin, reflecting less agility in managing operational expenses.

The net margin trajectory highlights LLY's stable increase from 22.0% to 23.5%, indicating effective management of expenses and tax strategies throughout varying economic conditions. MRK's dramatic rise in net margin from 1.9% to 26.7% showcases its ability to capitalize on operational efficiencies and robust revenue growth post-COVID.

Tracking return trends through various economic regimes provides valuable insights into capital efficiency and the ability of firms to create shareholder value. Understanding how these metrics evolve through different market conditions is crucial for gauging a company's resilience and strategic positioning.

During the low-rate era from 2019 to early 2021, Eli Lilly and Company (LLY) and Merck & Co., Inc. (MRK) demonstrated significant improvements in return metrics. LLY's ROIC improved from 21.9% in 2010 to 26.4% in 2024, while MRK showed a remarkable increase from 2.2% to 19.0% in the same period. Pfizer Inc. (PFE), in contrast, maintained a stable ROIC of 9.1% to 9.3%, indicating less dynamism. The COVID-19 pandemic temporarily disrupted all companies, but MRK emerged with impressive recovery metrics. By 2023, MRK's ROA soared to 14.6%, reflecting its ability to leverage assets effectively in a challenging environment. As the economy transitioned into a recovery phase post-COVID, both LLY and MRK capitalized on their innovative pipelines, resulting in improved profitability. However, the rising rate environment beginning in 2022 exposed vulnerabilities for PFE, as its ROE declined slightly from 9.4% to 9.1%. In contrast, LLY and MRK continued to enhance their ROE, with LLY surging from 40.8% to 74.6% and MRK from 1.6% to 37.0%. This divergence illustrates how certain companies adapted successfully to macroeconomic headwinds, maintaining robust returns despite rising interest rates and inflationary pressures.

The ROIC trajectory reveals that LLY and MRK held up well during the 2022 rate stress, maintaining impressive returns amid rising costs of capital. With the cost of capital increasing, achieving 20%+ ROIC became even more critical, and both LLY and MRK succeeded in this regard.

ROA trends indicate that asset efficiency fluctuated, particularly for MRK, which dramatically improved its ROA from 0.8% in 2010 to 14.6% in 2024. Conversely, LLY's ROA declined from 16.4% to 13.5%, suggesting challenges in asset utilization amidst enhanced capital expenditures.

The ROE trajectory highlights the impact of leverage and rate changes, with LLY's ROE significantly benefiting from operational improvements and share repurchase programs. The DuPont analysis illustrates that LLY's growth in net profit margins and asset turnover contributed to its exceptional ROE performance, contrasting with PFE's stagnation.

Understanding value creation history across different rate regimes is crucial, as a low-rate environment can mask underlying inefficiencies, while a high-rate context reveals the true economic viability of businesses. This analysis provides insight into how companies performed through varying economic conditions, particularly in the face of rising costs of capital.

Between 2019 and 2021, the pharmaceutical sector enjoyed an era of low interest rates, which made it easier for companies to achieve positive ROIC-WACC spreads. Eli Lilly and Company (LLY) demonstrated remarkable value creation during this period, maintaining a strong spread that increased from 12.4% in 2010 to 16.9% by 2024. Conversely, Pfizer Inc. (PFE) struggled to achieve consistent value creation, only managing a slight improvement in its negative spread from -0.4% to -0.2%, indicating persistent challenges despite favorable financial conditions. Merck & Co., Inc. (MRK), however, underwent a significant transformation, moving from a concerning -7.3% in 2010 to a positive 9.5% spread by 2024, showcasing a robust turnaround in its value creation strategy. As the economic landscape shifted in 2022 and 2023, with rising interest rates compressing spreads, the true resilience of these companies was tested. LLY continued to create value despite the increased cost of capital, reflecting its strong operational efficiency and strategic positioning. In contrast, PFE's ability to generate value remained stagnant, highlighting vulnerabilities that were masked during the low-rate era. MRK, however, successfully transitioned into a value creator, demonstrating adaptability as it capitalized on its strategic initiatives and improved operational metrics, which allowed it to thrive even in a more challenging environment.

The ROIC-WACC spreads across these companies reflected significant changes as interest rates rose, particularly during the normalization phase beginning in 2022. LLY maintained its status as a value creator, while PFE's spread remained marginally negative, revealing its struggles to adapt to higher costs of capital. MRK's turnaround is particularly noteworthy, as it emerged from a substantial deficit to achieve a positive spread, demonstrating its resilience in a rising rate environment.

Merck's journey from a significant value destroyer to a robust value creator highlights a remarkable turnaround driven by changes in the rate regime and effective strategic adjustments. This shift illustrates how operational improvements can drive value creation, even in tougher economic climates.

This multi-year, multi-regime profitability journey reveals that LLY and MRK are the 'all-weather' performers, adept at maintaining and improving profitability through various economic conditions. Their substantial gains in ROE and operating margins during the recovery signal a solid foundation for future growth, while PFE's stable performance provides a contrast, showcasing a more conservative approach amidst fluctuating market dynamics.